Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$0.75
-$0.01(-1.32%)
At close: 4:00 PM EDT
$0.75
-$0.01(-1.32%)
Day’s Range― - ―
52-Week Range$0.56 - $4.01
Previous Close$2.13
Volume48.12K
Average Volume (3M)206.82K
Market Cap
$22.52M
Enterprise Value$116.37
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta3.19
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Placental Cell Therapy PlatformThe placental-tissue platform supports potentially scalable, off-the-shelf therapies across oncology and regenerative medicine. Reusable sourcing, processing and biomaterial capabilities may create a durable foundation for multiple candidates and commercial partnerships.
Improved Loss And Cash-burn ProfileAlthough Celularity remains cash-flow negative, materially lower outflows than in earlier periods could extend operating runway and improve resource allocation. Sustained burn reduction would lessen the funding required to advance the pipeline.
Leadership ConsolidationConcentrating operational, legal and strategic responsibilities among experienced internal leaders may improve execution and governance during financing and regulatory complexity. The benefit depends on whether the revised structure delivers clearer commercial progress.
Bears Say
Revenue Contraction And Persistent LossesThe revenue decline indicates weak or inconsistent commercialization, while recurring operating losses show that the platform has not yet reached economic scale. This limits internal funding capacity and increases dependence on future financing or partnerships.
Negative Equity And External Funding DependenceNegative equity and continuing cash burn materially reduce financial flexibility. Reliance on secured insider financing suggests limited access to internally generated funds and raises the risk of refinancing pressure, dilution or tighter operating choices.
Nasdaq Compliance And Listing RiskFailure to regain Nasdaq’s bid-price requirement could lead to delisting, weakening access to public capital markets and reducing visibility with investors and partners. The compliance process adds an enduring financing and execution constraint.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.56 and its highest was $4.01 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $22.52M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 223 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Celularity
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
14.57% Insiders
2.63% Mutual Funds
3.05% Other Institutional Investors
77.60% Public Companies and
Individual Investors